# US 6,730,697 B2 · Dihydrothiaphenanthrenecarbonylguanidines: composition, process of making, and use as medicament or diagnostic aid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,697 B2
- Document ID: US6730697B2
- Status: Granted
- Kind: B2
- Application number: 10/350,520
- Filed: 2003-01-23
- Published: 2003-09-25
- Granted: 2004-05-04
- Earliest claimed: 2002-02-07
- Assignees: Aventis Pharma Deutschland GmbH
- Inventors: Heinz-Werner Kleemann; Peter Below
- Web page: https://patentgrep.com/patent/US6730697B2

## CPC

- C07D 335/10: Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Dihydrothiaphenanthrenecarbonylguanidine compound of formula I These compounds are potentially suitable as antiarrythmic medicaments with a cardioprotective component for prophylaxis of an infarction and treatment of infarction, and for treatment of angina pectoris. They may also inhibit in a preventive manner the pathophysiological processes involved in the development of ischemia-induced damage, especially in the initiation of ischemia-induced cardiac arrhythmias.

## Claims

### Claim 1

A dihydrothiaphenanthrenecarbonylguanidine compound of formula I or a pharmaceutically suitable salt of said compound:
wherein:
R1 and R3 are independently selected from the group consisting of hydrogen, —(C1-C4)-alkyl, —(C1-C4)-alkoxy, —F, —Cl, —Br, —I, —CN, —NR10R11, —Op—(CH2)n—(CF2)x—CF3, and —(SOm)p—(CH2)n—(CF2)x—CF3, wherein:
R10 and R11 are independently selected from the group consisting of hydrogen, —(C1-C4)-alkyl and —(CH2)n—(CF2)x—CF3,
m=0, 1 or 2,
n=0, 1, 2, 3, 4, 5 or 6,
x=0 or 1, and
p=0 or 1;
R2 is selected from the group consisting of hydrogen, —F, —Cl, —Br, —I, —CN, —(C1-C4)-alkyl, methoxy, and —(C3-C8)-cycloalkyl;
R4 and R5 are independently selected from the group consisting of hydrogen and —(C1-C4) alkyl;
R6, R7, R8 and R9 are independently selected from the group consisting of hydrogen, —(C1-C4)-alkyl; —(C1-C4)-alkoxy, —F, —Cl, —Br, —I, —CN, —NR12R13, —Oq—(CH2)r—(CF2)s—CF3 and —(SOw)t—(CH2)u—(CF2)v—CF3, wherein:
R12 and R13 are independently selected from the group consisting of hydrogen and —(C1-C4)-alkyl,
w=0, 1 or 2,
r=0, 1, 2, 3, 4, 5, or 6,
u=0, 1, 2, 3, 4, 5, or 6,
q=0 or 1
s=0 or 1
t=0 or 1, and
v=0 or 1; or
R6 and R7, together with ring 1, form a naphthalene system and R8 and R9 remain as defined above; or
R7 and R8, together with ring 1, form a naphthalene system and R6 and R9 remain as defined above; or
R8 and R9, together with ring 1, form a naphthalene system and R6 and R7 remain as defined above; and
A is selected from the group consisting of —S—, —SO— and —SO2—.

### Claim 2 (depends on 1)

A compound of claim 1 or a pharmaceutically suitable salt of said compound, wherein:
R1 and R3 are independently selected from the group consisting of hydrogen, methyl, ethyl, methoxy, ethoxy, —F, —Cl, —CN, —NR10R11, —Op—(CH2)n—CF3 and —(SOm)p—(CH2)n—CF3, wherein:
R10 and R11 are independently selected from the group consisting of hydrogen, methyl, ethyl and —CH2—CF3,
m=0, 1 or 2,
n=0, 1, 2 or 3, and
p=0 or 1;
R2 is selected from the group consisting of hydrogen, —F, —Cl, —CN, —(C1-C4)-alkyl, methoxy, and —(C3-C6)-cycloalkyl;
R4 and R5 are independently selected from the group consisting of hydrogen, methyl and ethyl;
R6, R7, R8 and R9 are independently selected from the group consisting of hydrogen, —(C1-C4)-alkyl, methoxy, ethoxy, —F, —Cl, —CN, —NR12R13, —Oq—(CH2)r—CF3 and —(SOw)t—(CH2)u—CF3, wherein:
R12 and R13 are independently selected from the group consisting of hydrogen, methyl and ethyl,
w=0, 1 or 2;
r=0, 1, 2, or 3,
u=0, 1, 2, or 3,
q=0 or 1, and
t=0 or 1; or
R6 and R7, together with ring 1, form a naphthalene system and R8 and R9 remain as defined in the preceding section of this claim; or
R7 and R8, together with ring 1, form a naphthalene system and R6 and R9 remain as defined in the preceding section of this claim; or
R8 and R9, together with ring 1, form a naphthalene system and R6 and R7 remain as defined in the preceding section of this claim; and
A is selected from the group consisting of —S—, —SO— and —SO2—.

### Claim 3 (depends on 1)

A compound of claim 1 or and a pharmaceutically suitable salt of said compound, wherein:
R1 is selected from the group consisting of hydrogen, methyl, ethyl, methoxy, ethoxy, —F, —Cl , —NR10R11, —Op—(CH2)n—CF3 and —(SOm)p—(CH2)n—CF3, wherein R10 and R11 are independently selected from the group consisting of hydrogen, methyl, ethyl and —CH2—CF3, m=0, 1 or 2, n=0 or 1, p=0 or 1;
R2 is selected from the group consisting of hydrogen, —F, —Cl, methyl, and —(C3-C6)-cycloalkyl;
R3, R4 and R5 are hydrogen;
R6, R7, R8 and R9 are independently selected from the group consisting of hydrogen, methyl, methoxy, ethoxy, —F, —Cl, —NR(12)R(13), —Oq—(CH2)r—CF3 and —(SOw)t—(CH2)u—CF3, wherein
R12 and R13 are independently selected from the group consisting of hydrogen, methyl or ethyl; w=0, 1 or 2; q, r, t and u are independently zero or one; or
R6 and R7, together with ring 1, form a naphthalene system and R8 and R9 remain as defined in the preceding section of this claim; or
R7 and R8, together with ring 1, form a naphthalene system and R6 and R9 remain as defined in the preceding section of this claim; or
R8 and R9, together with ring 1, form a naphthalene system and R6 and R7 remain as defined in the preceding section of this claim; and
A is selected from the group consisting of —S—, —SO— and —SO2—.

### Claim 4 (depends on 1)

A compound of claim 1 or a pharmaceutically suitable salt of said compound, wherein:
R1 is selected from the group consisting of hydrogen, methyl, methoxy, ethoxy, —Cl, —NR10R11, —O—CH2—CF3 and —(SOm)p—(CH2)n—CF3, wherein R(10) and R(11) are independently selected from the group consisting hydrogen, methyl, ethyl and —CH2—CF3; m is 0, 1 or 2; p is 0 or 1;
R2 is selected from the group consisting of hydrogen, —F, —Cl and methyl;
R3, R4 and R5 are hydrogen;
R6, R7, R8 and R9 are independently selected from the group consisting of hydrogen, methyl; methoxy, ethoxy, —F, —Cl, —O—CH2—CF3 and —(SOw)t—(CH2)u—CF3, wherein w is 0, 1 or 2; t and u are independently zero or one; or
R6 and R7, together with ring 1, form a naphthalene system and R8 and R9 remain as defined in the preceding section of this claim; or
R7 and R8, together with ring 1, form a naphthalene system and R6 and R9 remain as defined in the preceding section of this claim; or
R8 and R9, together with ring 1, form a naphthalene system and R6 and R7 remain as defined in the preceding section of this claim; and
A is —SO2—.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound or a salt of a compounds of claim 1 and a suitable and physiologically tolerated carrier substance.

### Claim 6 (depends on 1)

A method for treatment and prophylaxis of a disorder caused by ischemic states, comprising administering an effective amount of a compound or a salt of a compound of claim 1 in a suitable dosage form.

### Claim 7 (depends on 6)

A method of claim 6, wherein said disorder is myocardial infarction or arrhythmias.

### Claim 8 (depends on 6)

A method of claim 6, wherein said disorder is angina pectoris.

### Claim 9 (depends on 6)

A method of claim 6, wherein said disorder is ischemic states of the heart.

### Claim 10 (depends on 6)

A method of claim 6, wherein said disorder is ischemic states of the peripheral and central nervous system or stroke.

### Claim 11 (depends on 6)

A method of claim 6, wherein said disorder is ischemic states of the peripheral organs and limbs.

### Claim 12 (depends on 6)

A method of claim 6, wherein said disorder is a state of shock.

### Claim 13 (depends on 5)

A pharmaceutical composition of claim 5, useful during surgical operations or organ transplantations.

### Claim 14 (depends on 5)

A pharmaceutical composition of claim 5, useful for preservation and storage of transplants for surgical procedures.

### Claim 15 (depends on 5)

A pharmaceutical composition of claim 5, useful for treatment of disorders in which cell proliferation represents a primary or secondary cause.

### Claim 16 (depends on 5)

A pharmaceutical composition of claim 5, useful for treatment or prophylaxis of disorders of lipid metabolism.
